Cargando…

Tumour-reactive T cell subsets in the microenvironment of ovarian cancer

BACKGROUND: Solid malignancies are frequently infiltrated with T cells. The success of adoptive cell transfer (ACT) with expanded tumour-infiltrating lymphocytes (TILs) in melanoma warrants its testing in other cancer types. In this preclinical study, we investigated whether clinical-grade TILs coul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Westergaard, Marie Christine Wulff, Andersen, Rikke, Chong, Chloé, Kjeldsen, Julie Westerlin, Pedersen, Magnus, Friese, Christina, Hasselager, Thomas, Lajer, Henrik, Coukos, George, Bassani-Sternberg, Michal, Donia, Marco, Svane, Inge Marie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461863/ https://www.ncbi.nlm.nih.gov/pubmed/30718808 http://dx.doi.org/10.1038/s41416-019-0384-y

Ejemplares similares

Correction: Tumour-reactive T cell subsets in the microenvironment of ovarian cancer
por: Westergaard, Marie Christine Wulff, et al.
Publicado: (2019)

Polyfunctional incompletely differentiated CD8+ T cells accumulates after adoptive transfer of tumor-infiltrating lymphocytes and establish immunological memory in patients with metastatic melanoma
por: Donia, Marco, et al.
Publicado: (2015)

Changes in the Tumor Immune Microenvironment during Disease Progression in Patients with Ovarian Cancer
por: Westergaard, Marie Christine Wulff, et al.
Publicado: (2020)

CTLA-4 blockade boosts the expansion of tumor-reactive CD8(+) tumor-infiltrating lymphocytes in ovarian cancer
por: Friese, Christina, et al.
Publicado: (2020)

Long-term follow-up of anti-PD-1 naïve patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab
por: Lorentzen, Cathrine Lund, et al.
Publicado: (2023)

Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors – A phase I trial
por: Lorentzen, Cathrine Lund, et al.
Publicado: (2022)

Durable Clinical Responses and Long-Term Follow-Up of Stage III–IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Study—A Brief Research Report
por: Kjeldsen, Julie Westerlin, et al.
Publicado: (2018)

Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma
por: Borch, Troels Holz, et al.
Publicado: (2021)

Effects of Ipilimumab on expanded tumor infiltrating lymphocytes in patients with stage IV malignant melanoma
por: Bjørn, Jon, et al.
Publicado: (2013)

First in man study: Bcl-Xl_42-CAF(®)09b vaccines in patients with locally advanced prostate cancer
por: Mørk, Sofie Kirial, et al.
Publicado: (2023)

Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma
por: Borch, Troels Holz, et al.
Publicado: (2020)

Correction: Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma
por: Bjoern, Jon, et al.
Publicado: (2018)

Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma
por: Bjoern, Jon, et al.
Publicado: (2017)

A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
por: Kjeldsen, Julie Westerlin, et al.
Publicado: (2021)

Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
por: Kjeldsen, Julie Westerlin, et al.
Publicado: (2022)

BRAF inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer
por: Donia, Marco, et al.
Publicado: (2012)

T cell therapy in combination with Vemurafenib in BRAF mutated metastatic melanoma patients
por: Borch, Troels Holz, et al.
Publicado: (2014)

Intratumoral T-cell and B-cell receptor architecture associates with distinct immune tumor microenvironment features and clinical outcomes of anti-PD-1/L1 immunotherapy
por: Schina, Aimilia, et al.
Publicado: (2023)

Adoptive cell therapy in combination with checkpoint inhibitors in ovarian cancer
por: Kverneland, Anders Handrup, et al.
Publicado: (2020)

Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types
por: Kverneland, Anders Handrup, et al.
Publicado: (2021)

Qualitative Analysis of Tumor-Infiltrating Lymphocytes across Human Tumor Types Reveals a Higher Proportion of Bystander CD8(+) T Cells in Non-Melanoma Cancers Compared to Melanoma
por: Gokuldass, Aishwarya, et al.
Publicado: (2020)

Analysis of Vδ1 T cells in clinical grade melanoma-infiltrating lymphocytes
por: Donia, Marco, et al.
Publicado: (2012)

Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model
por: Jespersen, Henrik, et al.
Publicado: (2017)

Sensitive Immunopeptidomics by Leveraging Available Large-Scale Multi-HLA Spectral Libraries, Data-Independent Acquisition, and MS/MS Prediction
por: Pak, HuiSong, et al.
Publicado: (2021)

Real-world evidence to guide healthcare policies in oncology
por: Donia, Marco, et al.
Publicado: (2019)

Adoptive cell therapy with tumor infiltrating lymphocytes and intermediate dose IL-2 for metastatic melanoma
por: Andersen, Rikke, et al.
Publicado: (2014)

‘Hotspots’ of Antigen Presentation Revealed by Human Leukocyte Antigen Ligandomics for Neoantigen Prioritization
por: Müller, Markus, et al.
Publicado: (2017)

High-throughput and Sensitive Immunopeptidomics Platform Reveals Profound Interferonγ-Mediated Remodeling of the Human Leukocyte Antigen (HLA) Ligandome
por: Chong, Chloe, et al.
Publicado: (2018)

B Cells and Tertiary Lymphoid Structures: Friends or Foes in Cancer Immunotherapy?
por: Lauss, Martin, et al.
Publicado: (2022)

Improved Progression-Free Long-Term Survival of a Nation-Wide Patient Population with Metastatic Melanoma
por: Soerensen, Anne Vest, et al.
Publicado: (2020)

Estimating the Contribution of Proteasomal Spliced Peptides to the HLA-I Ligandome*
por: Mylonas, Roman, et al.
Publicado: (2018)

Deciphering HLA-I motifs across HLA peptidomes improves neo-antigen predictions and identifies allostery regulating HLA specificity
por: Bassani-Sternberg, Michal, et al.
Publicado: (2017)

Rapid Identification of the Tumor-Specific Reactive TIL Repertoire via Combined Detection of CD137, TNF, and IFNγ, Following Recognition of Autologous Tumor-Antigens
por: Draghi, Arianna, et al.
Publicado: (2021)

Analysis of Secondary Structure Biases in Naturally Presented HLA-I Ligands
por: Perez, Marta A. S., et al.
Publicado: (2019)

Identification of a cyclin B1-derived CTL epitope eliciting spontaneous responses in both cancer patients and healthy donors
por: Andersen, Rikke Sick, et al.
Publicado: (2010)

Broadening the repertoire of melanoma-associated T-cell epitopes
por: Frøsig, Thomas Mørch, et al.
Publicado: (2015)

Deciphering the landscape of phosphorylated HLA-II ligands
por: Solleder, Marthe, et al.
Publicado: (2022)

Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma
por: Lauss, Martin, et al.
Publicado: (2017)

Author Correction: Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma
por: Lauss, Martin, et al.
Publicado: (2020)

Genetic Biomarkers in Melanoma of the Ocular Region: What the Medical Oncologist Should Know
por: Bol, Kalijn Fredrike, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_i0iq5filv9ipkiuuun0hlo4mr6